Provided by Tiger Trade Technology Pte. Ltd.

Jatt II Acquisition Corp. (Stock-Only SPAC)

10.50
-0.3100-2.87%
Volume:18.67K
Turnover:197.70K
Market Cap:81.90M
PE:- -
High:10.99
Open:10.99
Low:10.42
Close:10.81
52wk High:23.76
52wk Low:9.99
Shares:7.80M
Float Shares:6.03M
Volume Ratio:0.69
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:-1.19%
PB:-10.74
PE(LYR):- -

Loading ...

Jatt Iii Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering

THOMSON REUTERS
·
Aug 28

Jatt III Acquisition Corp Announces Pricing of $60 Million IPO

Reuters
·
Aug 26

Jatt Ii Acquisition Corp - Iii Acquisition Corp Prices IPO of 6,000,000 Shares at $10 Each

THOMSON REUTERS
·
Aug 26

Jatt II Acquisition Corp trading resumes

TIPRANKS
·
Aug 21

NASDAQ Trade Halt Volatility Trading Pause at 09:48 Am

Reuters
·
Aug 21

JATT II Acquisition Corp Ordinary Shares trading halted, volatility trading pause

TIPRANKS
·
Jun 29

NASDAQ Trade Halt Volatility Trading Pause at 09:32 Am

Reuters
·
Jun 29

JATT II Acquisition Agrees to Merge with Talawar Therapeutics in Deal Backed by USD 225 Million PIPE

Reuters
·
Jun 29

Jatt Ii Acquisition Corp - Business Combination Expected to Close in H2 2026

THOMSON REUTERS
·
Jun 29

Jatt Ii Acquisition Corp: Available Cash to Combined Co at Closing Anticipated to Fund Tala-125 Through Phase 2B Study Data Readout in H2 2028

THOMSON REUTERS
·
Jun 29

Talawar Therapeutics and Jatt Ii Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-class Bispecifics for I&I Diseases

THOMSON REUTERS
·
Jun 29

Jatt Ii Acquisition Corp: Tala-125 Expected to Enter Clinic in Q1 2027, Interim Phase 1 Data Anticipated in Q4 2027

THOMSON REUTERS
·
Jun 29

Jatt Ii Acquisition Corp - Combined Company to Trade on NASDAQ Under Ticker 'tlwr'

THOMSON REUTERS
·
Jun 29

Jatt Ii Acquisition Corp - Combined Company Expects to Receive $285 Mln at Closing

THOMSON REUTERS
·
Jun 29

Press Release: Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-class Bispecifics for I&I Diseases

Dow Jones
·
Jun 29

JATT II Acquisition posts net loss of $68,793 for Q1 FY26

Reuters
·
May 30

BRIEF-Jatt II Acquisition Announces Closing Of $60 Million IPO

Reuters
·
Apr 21

JATT II Acquisition closes $60 million IPO priced at $10 per share

Reuters
·
Apr 21

Jatt Ii Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering

THOMSON REUTERS
·
Apr 21